Expert Review of Neurotherapeutics最新文献

UK Medical Cannabis Registry: a cohort study of patients prescribed cannabis-based oils and dried flower for generalised anxiety disorder. 英国医用大麻登记处：对开具大麻精油和干花治疗广泛性焦虑症的患者进行的队列研究。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-11-11 DOI: 10.1080/14737175.2024.2423634

John Warner-Levy, Simon Erridge, Evonne Clarke, Katy McLachlan, Ross Coomber, Muhammed Asghar, Karl Bexley, Urmila Bhoskar, Matthieu Crews, Andrea De Angelis, Muhammad Imran, Fariha Kamal, Laura Korb, Gracia Mwimba, Simmi Sachdeva-Mohan, Gabriel Shaya, James J Rucker, Mikael H Sodergren

{"title":"UK Medical Cannabis Registry: a cohort study of patients prescribed cannabis-based oils and dried flower for generalised anxiety disorder.","authors":"John Warner-Levy, Simon Erridge, Evonne Clarke, Katy McLachlan, Ross Coomber, Muhammed Asghar, Karl Bexley, Urmila Bhoskar, Matthieu Crews, Andrea De Angelis, Muhammad Imran, Fariha Kamal, Laura Korb, Gracia Mwimba, Simmi Sachdeva-Mohan, Gabriel Shaya, James J Rucker, Mikael H Sodergren","doi":"10.1080/14737175.2024.2423634","DOIUrl":"https://doi.org/10.1080/14737175.2024.2423634","url":null,"abstract":"Background: Generalized anxiety disorder (GAD) is a common mental health condition. The endocannabinoid system has become a focus for new therapies, increasing interest in cannabis-based medicinal products (CBMPs). This study uses data from the UK Medical Cannabis Registry (UKMCR) to investigate real-world outcomes and safety of different CBMP formulations in GAD patients.Methods: This study analyzed patient-reported outcomes from 302 GAD patients prescribed CBMPs (oil-based, dried flower, or a combination). Anxiety (GAD-7), sleep quality (SQS), and quality of life (EQ-5D-5 L) were assessed at 1, 3, 6, and 12 months. Adverse events were recorded.Results: All CBMP formulations were associated with improvements in anxiety, sleep, and quality of life over 12 months (p < 0.050). At 12 months, there were no significant differences in outcomes between formulations (p > 0.050). The majority of reported adverse events (n = 707) were mild (n = 343) or moderate (n = 285) in severity, with no life-threatening events observed.Conclusion: This study provides real-world evidence supporting the potential of CBMPs for improving GAD symptoms. Patients prescribed both oil-based and dried flower formulations have similar outcomes over 12 months. Further research is needed to determine the optimal CBMP formulation and long-term effects.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1-10"},"PeriodicalIF":3.4,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142615523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Can pharmacotherapy help to reduce trichotillomania? 药物疗法有助于减轻毛发躁动症吗？

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-11-01 Epub Date: 2024-09-04 DOI: 10.1080/14737175.2024.2398471

Michael Thomson, Verinder Sharma

引用次数: 0

Menopause and its impact on the effectiveness of fremanezumab for migraine prophylaxis: post-hoc analysis of a prospective, real-world Greek registry. 更年期及其对氟马尼珠单抗预防偏头痛疗效的影响：对希腊前瞻性真实世界登记的事后分析。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-11-01 Epub Date: 2024-09-16 DOI: 10.1080/14737175.2024.2403576

Andreas A Argyriou, Emmanouil V Dermitzakis, Georgia Xiromerisiou, Dimitrios Rikos, Dimitrios Rallis, Panagiotis Soldatos, Pantelis Litsardopoulos, Anna P Andreou, Michail Vikelis

{"title":"Menopause and its impact on the effectiveness of fremanezumab for migraine prophylaxis: post-hoc analysis of a prospective, real-world Greek registry.","authors":"Andreas A Argyriou, Emmanouil V Dermitzakis, Georgia Xiromerisiou, Dimitrios Rikos, Dimitrios Rallis, Panagiotis Soldatos, Pantelis Litsardopoulos, Anna P Andreou, Michail Vikelis","doi":"10.1080/14737175.2024.2403576","DOIUrl":"10.1080/14737175.2024.2403576","url":null,"abstract":"Objective: This post-hoc analysis of data extracted from a prospective study aimed to explore for the first time if the efficacy of fremanezumab in preventing difficult-to-treat migraine, according to ICHD-III, would differ between pre-menopausal and post-menopausal women.Methods: A total of 171 (aged 18-70 years) fremanezumab-treated female migraine patients for six consecutive months were classified to those at pre-menopausal (n = 82) or post-menopausal (n = 89). Monthly headache days (MHD), disability, and quality of life (QOL) outcomes were assessed at baseline and at week 24 post-fremanezumab within subgroups and were then compared between them. Safety and tolerability were also assessed.Results: In both groups, fremanezumab demonstrated significant reductions in MHDs, reduced disability, and higher QOL scores at week 24 post-treatment, compared to baseline. However, the between-subgroup comparison documented that pre-menopausal women and those at post-menopausal comparably benefited with significant reductions in overall MHDs (p = 0.883). Less disability, according to MIDAS (p = 0.696) and HIT-6 scores (p = 0.912), as well as higher QOL scores at week 24 post-fremanezumab, were also comparably evident in both groups. Safety was excellent across both subgroups.Conclusion: Fremanezumab can be considered a very effective treatment option for preventing migraines in difficult-to-treat women, aged 18-70 years, regardless of their menopausal status.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1119-1126"},"PeriodicalIF":3.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142282633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The major challenges with pharmacologic management of chronic traumatic encephalopathy. 慢性创伤性脑病药物治疗的主要挑战。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-11-01 Epub Date: 2024-08-04 DOI: 10.1080/14737175.2024.2387264

Brendan P Campbell, Katherine W Turk, Andrew E Budson

引用次数: 0

Cerebrospinal fluid in the differential diagnosis of Alzheimer's disease: an update of the literature. 阿尔茨海默病鉴别诊断中的脑脊液：文献更新。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-11-01 Epub Date: 2024-09-04 DOI: 10.1080/14737175.2024.2400683

Tina Milos, Barbara Vuic, Nikola Balic, Vladimir Farkas, Gordana Nedic Erjavec, Dubravka Svob Strac, Matea Nikolac Perkovic, Nela Pivac

{"title":"Cerebrospinal fluid in the differential diagnosis of Alzheimer's disease: an update of the literature.","authors":"Tina Milos, Barbara Vuic, Nikola Balic, Vladimir Farkas, Gordana Nedic Erjavec, Dubravka Svob Strac, Matea Nikolac Perkovic, Nela Pivac","doi":"10.1080/14737175.2024.2400683","DOIUrl":"10.1080/14737175.2024.2400683","url":null,"abstract":"Introduction: The importance of cerebrospinal fluid (CSF) biomarkers in Alzheimer's disease (AD) diagnosis is rapidly increasing, and there is a growing interest in the use of CSF biomarkers in monitoring the response to therapy, especially in the light of newly available approaches to the therapy of neurodegenerative diseases.Areas covered: In this review we discuss the most relevant measures of neurodegeneration that are being used to distinguish patients with AD from healthy controls and individuals with mild cognitive impairment, in order to provide an overview of the latest information available in the scientific literature. We focus on markers related to amyloid processing, markers associated with neurofibrillary tangles, neuroinflammation, neuroaxonal injury and degeneration, synaptic loss and dysfunction, and markers of α-synuclein pathology.Expert opinion: In addition to neuropsychological evaluation, core CSF biomarkers (Aβ42, t-tau, and p-tau181) have been recommended for improvement of timely, accurate and differential diagnosis of AD, as well as to assess the risk and rate of disease progression. In addition to the core CSF biomarkers, various other markers related to synaptic dysfunction, neuroinflammation, and glial activation (neurogranin, SNAP-25, Nfl, YKL-40, TREM2) are now investigated and have yet to be validated for future potential clinical use in AD diagnosis.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1063-1079"},"PeriodicalIF":3.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142132260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Brain atrophy assessment in multiple sclerosis: technical- and subject-related barriers for translation to real-world application in individual subjects. 多发性硬化症的脑萎缩评估：将技术和受试者相关障碍转化为个体受试者的实际应用。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-11-01 Epub Date: 2024-09-04 DOI: 10.1080/14737175.2024.2398484

Robert Zivadinov, Ashley Tranquille, Jack A Reeves, Michael G Dwyer, Niels Bergsland

{"title":"Brain atrophy assessment in multiple sclerosis: technical- and subject-related barriers for translation to real-world application in individual subjects.","authors":"Robert Zivadinov, Ashley Tranquille, Jack A Reeves, Michael G Dwyer, Niels Bergsland","doi":"10.1080/14737175.2024.2398484","DOIUrl":"10.1080/14737175.2024.2398484","url":null,"abstract":"Introduction: Brain atrophy is a well-established MRI outcome for predicting clinical progression and monitoring treatment response in persons with multiple sclerosis (pwMS) at the group level. Despite the important progress made, the translation of brain atrophy assessment into clinical practice faces several challenges.Areas covered: In this review, the authors discuss technical- and subject-related barriers for implementing brain atrophy assessment as part of the clinical routine at the individual level. Substantial progress has been made to understand and mitigate technical barriers behind MRI acquisition. Numerous research and commercial segmentation techniques for volume estimation are available and technically validated, but their clinical value has not been fully established. A systematic assessment of subject-related barriers, which include genetic, environmental, biological, lifestyle, comorbidity, and aging confounders, is critical for the interpretation of brain atrophy measures at the individual subject level. Educating both medical providers and pwMS will help better clarify the benefits and limitations of assessing brain atrophy for disease monitoring and prognosis.Expert opinion: Integrating brain atrophy assessment into clinical practice for pwMS requires overcoming technical and subject-related challenges. Advances in MRI standardization, artificial intelligence, and clinician education will facilitate this process, improving disease management and potentially reducing long-term healthcare costs.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1081-1096"},"PeriodicalIF":3.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142132259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Relationship between anti-seizure medication and behaviors that challenge in older persons with intellectual disability and epilepsy: a review. 抗癫痫药物与智障和癫痫老年人的挑战行为之间的关系：综述。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-11-01 Epub Date: 2024-08-19 DOI: 10.1080/14737175.2024.2393322

Seungyoun Moon, Lance Watkins, Maire O'Dwyer, Rohit Shankar

{"title":"Relationship between anti-seizure medication and behaviors that challenge in older persons with intellectual disability and epilepsy: a review.","authors":"Seungyoun Moon, Lance Watkins, Maire O'Dwyer, Rohit Shankar","doi":"10.1080/14737175.2024.2393322","DOIUrl":"10.1080/14737175.2024.2393322","url":null,"abstract":"Introduction: There is increased focus on the negative impact of the overprescribing of medication, specifically psychotropic medication, including anti-seizure medications (ASM), in people with Intellectual Disability (ID). This is particularly important for the older adult population, where multi-morbidity and polypharmacy are more common. ASMs are associated with psychiatric and behavioral adverse effects. Furthermore, there is growing awareness of the anticholinergic burden for older adults with epilepsy and ID and the relationship with behaviors that challenge (BtC).Areas covered: This review defines the older adult population and outlines the relationship between epilepsy and ID. BtC is outlined in the context of the population and the relationship with ASMs. The evidence base to guide prescribing and de-prescribing for newer ASMs is also presented, including pragmatic data.Expert opinion: Polypharmacy, particularly psychotropics, are a mortality risk factor for older adults with epilepsy and ID. Therefore, any BtC requires a holistic assessment with a multi-disciplinary approach. This includes specific consideration of all prescribed medicines in the context of polypharmacy. There should be routine reviews, at least annually, for those aged 40 years and over particularly focused on anticholinergic burden and/or polypharmacy.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1097-1105"},"PeriodicalIF":3.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142003990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Novel techniques for early diagnosis and monitoring of Alzheimer's disease. 早期诊断和监测阿尔茨海默病的新技术。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-10-22 DOI: 10.1080/14737175.2024.2415985

Parul, Animesh Singh, Shubha Shukla

{"title":"Novel techniques for early diagnosis and monitoring of Alzheimer's disease.","authors":"Parul, Animesh Singh, Shubha Shukla","doi":"10.1080/14737175.2024.2415985","DOIUrl":"10.1080/14737175.2024.2415985","url":null,"abstract":"Introduction: Alzheimer's disease (AD) is the most common neurodegenerative disorder, which is characterized by a progressive loss of cognitive functions. The high prevalence, chronicity, and multimorbidity are very common in AD, which significantly impair the quality of life and functioning of patients. Early detection and accurate diagnosis of Alzheimer's disease (AD) can stop the illness from progressing thereby postponing its symptoms. Therefore, for the early diagnosis and monitoring of AD, more sensitive, noninvasive, straightforward, and affordable screening tools are needed.Areas covered: This review summarizes the importance of early detection methods and novel techniques for Alzheimer's disease diagnosis that can be used by healthcare professionals.Expert opinion: Early diagnosis assists the patient and caregivers to understand the problem establishing reasonable goals and making future plans together. Early diagnosis techniques not only help in monitoring disease progression but also provide crucial information for the development of novel therapeutic targets. Researchers can plan to potentially alleviate symptoms or slow down the progression of Alzheimer's disease by identifying early molecular changes and targeting altered pathways.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1-14"},"PeriodicalIF":3.4,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142461404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Expert guidance on the differential diagnosis of neuroleptic malignant syndrome. 神经安定剂恶性综合征鉴别诊断专家指导。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-10-18 DOI: 10.1080/14737175.2024.2417414

Laura Orsolini, Umberto Volpe

引用次数: 0

Using oral topiramate for primary generalized and focal-to-bilateral tonic-clonic seizures in patients 2 years of age and older: a review of the literature. 使用口服托吡酯治疗 2 岁及以上患者的原发性全身强直阵挛发作和局灶至双侧强直阵挛发作：文献综述。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-10-17 DOI: 10.1080/14737175.2024.2417417

Slobodan M Janković, Dobrivoje Stojadinović, Vera Dabanović

{"title":"Using oral topiramate for primary generalized and focal-to-bilateral tonic-clonic seizures in patients 2 years of age and older: a review of the literature.","authors":"Slobodan M Janković, Dobrivoje Stojadinović, Vera Dabanović","doi":"10.1080/14737175.2024.2417417","DOIUrl":"https://doi.org/10.1080/14737175.2024.2417417","url":null,"abstract":"Introduction: Topiramate is a drug belonging to the second generation of antiseizure arsenal, used to treat focal onset seizures without generalization, focal-to-bilateral tonic-clonic seizures, and primary generalized tonic-clonic seizures.Areas covered: The narrative evaluation of topiramate's clinical research that has been published in this article focuses on the medication's effectiveness and safety when used to treat primary generalized and focal-to-bilateral tonic-clonic seizures. From their founding to the present, the databases MEDLINE, SCOPUS, EBSCO, and GOOGLE SCHOLAR were searched.Expert opinion: Topiramate treatment has the obvious benefit of being effective in treating tonic-clonic seizures; nevertheless, it may have a drawback in that up to 56% of patients discontinue therapy due to its rather poor tolerability, particularly at doses exceeding 600 mg daily. Patients are most bothered by psychiatric and cognitive side effects, and then by appetite and weight decrease. While the onset of anorexia cannot be prevented by changing the dosage regimen, psychiatric and cognitive side effects can be mitigated by slowly titrating the topiramate dose.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1-9"},"PeriodicalIF":3.4,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142461406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0